Lovaza® and Microvascular Function in Type 2 Diabetes: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Lovaza® and Microvascular Function in Type 2 Diabetes (NCT00931879), a randomized phase 4 study. The primary outcome is Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude..

2. Clinical Question

3. Trial Design

This was a randomized, triple-masked, parallel-group phase 4 trial sponsored by Eastern Virginia Medical School. The registry lists the study as completed, with enrollment of 44. The start date is 2009-10 and the primary completion date is 2012-07. These registry entries describe the trial’s administrative design and status; they do not establish how participants were randomized or what masking procedures were used.

The trial compared omega-3-ethyl esters, identified in the arm description as 4 g of Lovaza per day, with placebo. The brief summary describes six months of treatment and says that efficacy would be evaluated after three and six months. The primary outcome timeframe is listed as one year. How the one-year timeframe relates to the stated treatment and assessment schedule is not reported in the registry record.

The arm descriptions specify males or non-pregnant, non-lactating females aged 18-80 years, with type 2 diabetes diagnosed at least two years earlier and triglyceride levels above 149 mg/dL. The brief summary identifies neuropathy and elevated triglyceride levels as features of the intended population. The record does not give a fuller account of eligibility criteria, participant flow, or the characteristics of those analyzed.

The primary outcome description states that 19 participants in each arm were analyzed. It lists conduction velocities and amplitudes across several nerves, while the outcome title emphasizes changes in conduction amplitude. The record lists nine outcome measures overall, but does not provide a numerical primary-outcome result or an analysis for these nerve measures. The analysis methods, including any covariate adjustment, are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The study was powered at 0.80 for a two-tail analysis with a sensitivity of a 30% delta in blood flow in 40 subjects. The standard deviation of the measurements was calculated at 45% of the treatment group mean. This assessment of variance could accommodate for 9% attrition or data loss in the study. 44 patients will be recruited in total.

6. Primary Endpoint

The registry lists the primary outcome as Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude., measured over One year.

The primary outcome is described as nerve conduction studies, specifically changes in conduction amplitude. Nerve conduction testing assesses electrical responses in nerves; amplitude is one feature of that response. The record lists tibial, median, peroneal, ulnar, and sural nerve measures, including motor and sensory measures. The stated unit is uV, and the outcome is described as a mean with standard error.

As general statistical context, nerve conduction measures can serve as physiological measures of nerve function. A change in amplitude may be relevant to a study of diabetic neuropathy, but interpreting such a measure requires the actual observed values, their variability, the timing of measurement, and a clearly specified comparison. The registry’s brief summary also describes endothelial-dependent and heat-induced vasodilation as study interests, but these are not the primary outcome as worded in the outcome record.

The registry names the timeframe as one year, while the brief summary describes efficacy assessments after three and six months and six months of treatment. It does not explain the relationship among these time points. Nor does it report numerical means, standard errors, treatment contrasts, confidence intervals, or p-values for the listed nerve measures. Consequently, the endpoint description identifies what was measured, but the registry record does not permit an estimate of the magnitude or precision of any treatment-group difference.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the primary measure as continuous: it is a mean for nerve conduction measures, with standard error as the stated dispersion measure. General statistical context: a mean describes the central value of measurements in a group. A standard error describes the uncertainty in an estimated mean, rather than the spread of individual participant measurements. Neither the means nor their standard errors are reported for the primary outcome, so the treatment contrast and its uncertainty cannot be reconstructed from the registry record.

What does a treatment contrast represent?

For a two-arm trial, a treatment contrast expresses how the outcome differs between the active-treatment and comparator groups. For a continuous outcome, the contrast might be expressed as a difference in mean change, if change is the specified measure and the relevant group means are available. General statistical context: an estimate is more informative when accompanied by an uncertainty interval, because the interval communicates the range of effect sizes compatible with the data under the analysis assumptions. The registry does not report a treatment contrast or confidence interval for the nerve conduction outcome. No recalculated estimate is therefore available from the recorded primary results.

What does randomization contribute?

Random allocation is intended to make treatment groups comparable, on average, with respect to measured and unmeasured characteristics at the start of a trial. That goal does not guarantee identical groups in a particular trial, especially when the analyzed groups are limited in size. The registry labels allocation as randomized, but does not report the sequence-generation method, allocation concealment, or baseline balance. Triple masking is also recorded, but the roles of the masked parties and the procedures used to maintain masking are not reported in the registry record. These missing details prevent a fuller assessment of the implementation of randomization and masking.

How should the multiple nerve measures be understood?

The primary outcome description names several nerve sites and includes conduction velocities and amplitudes. The outcome title emphasizes changes in conduction amplitude, and the registry lists nine outcome measures overall. General statistical context: when investigators test multiple outcomes or multiple related measures, the chance of at least one apparently unusual result can increase if each is evaluated separately. A prespecified hierarchy or multiplicity adjustment can help define how findings should be interpreted. The registry does not report a statistical plan or multiplicity procedure, so it is not possible to determine how the several measures were intended to be interpreted together.

What is and is not known about analysis populations?

The primary outcome description states that 19 participants in each arm were analyzed. This is an analysis count, not a complete account of participant flow. The record does not explain how many participants were randomized to each arm, whether all randomized participants contributed data, why any participant may have been excluded from an analysis, or how missing outcome measurements were handled. General statistical context: analysis populations can differ according to whether they include all randomized participants or only participants with observed measurements or specified protocol adherence. Those choices can affect interpretation, but the record does not identify the population definition used.

What do planning calculations mean?

General statistical context: a sample-size calculation is a planning exercise based on assumptions about an effect, variability, significance level, allocation, and analysis approach. It is not a measure of the probability that a completed trial detected an effect. Any planning illustration based on an observed effect is distinct from the trial’s original design justification. The registry does not report its sample-size justification, and no claim about observed power can be made from the outcome information recorded. The analysis plan, interim analyses, and handling of over-dispersion are not reported in the registry record; the latter is relevant to some types of outcomes but is not a basis for adding assumptions to this continuous-outcome description.

Finally, the registry lists a one-year timeframe for the primary outcome but describes treatment for six months and efficacy evaluations after three and six months. General statistical context: a clear time point is important because the meaning of a change depends on when it was assessed and what baseline or reference measurement was used. The record does not specify those details for the listed outcome. Together, the absence of numerical results and analytic details means that the stated design can be described, but the primary comparison cannot be independently assessed from the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists nine outcome measures, and the primary outcome description refers to several nerve sites and measures, including conduction velocities and amplitudes. It does not identify a hierarchy among those measures or report a multiplicity procedure. As general statistical context, multiplicity concerns arise when several outcomes or comparisons are examined, because interpreting each result as if it were the only test can overstate the evidence from an isolated finding. The registry record does not establish whether any adjustment or prespecified testing sequence was used.

The record says that 19 participants in each arm were analyzed for the primary outcome description. It does not report how many were randomized to each group, the number with missing measurements, reasons for missingness, or the method used to handle missing data. It also does not specify whether the analysis followed an intention-to-treat definition or another analysis-population rule. These details are important for understanding whether the analyzed participants represent the randomized comparison.

The record states that treatment was described for six months, efficacy assessments were planned after three and six months, and the primary outcome timeframe was one year. The relationship among these time points, including which measurements contributed to the reported endpoint, is not reported in the registry record. The statistical analysis plan, covariate adjustments, and any interim analyses are also not reported. Without these details, the handling of multiple measurements and incomplete data cannot be evaluated.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 3% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: atypical chest pain (5.3%), head trauma due to accidental fall (5.3%), hospitilization due to low blood pressure and fainting (5.3%), overnight stay in er for observation after experiencing chest pain (5.3%), planned surgery to treat achalasia/esophageal motility disorder (5.3%).

The registry reports serious adverse events for the placebo arm as 4 affected participants among 19 at risk, and for the Lovaza arm as 2 affected participants among 19 at risk. It reports other adverse events for placebo as 7 among 19 at risk, and for Lovaza as 8 among 19 at risk. These are separate registry counts; the record does not provide a statistical comparison or uncertainty estimates for them.

The serious-event terms listed include “Atypical Chest Pain,” “Head trauma due to accidental fall,” “Hospitilization due to low blood pressure and fainting,” “Overnight stay in ER for observation after experiencing chest pain,” “Planned surgery to treat Achalasia/Esophageal motility disorder,” and “Emergency Surgery to relieve bile duct obstruction.” Each listed term is paired in the registry with 5.3%. The record does not explain whether a participant could contribute more than one event or how the term-level percentages were calculated, so they should not be interpreted as mutually exclusive categories or summed.

Deaths are recorded as null for both arms. Null does not establish that no deaths occurred; it means a death count is not reported in the registry record. The adverse-event figures do not establish causation or provide a complete assessment of comparative safety.

12. What the Result Does, and Does Not, Mean

The registry record describes a randomized comparison of Lovaza and placebo in people with type 2 diabetes and elevated triglyceride levels, with neuropathy identified in the study summary. It identifies nerve conduction measures as the primary outcome and states that 19 participants in each arm were analyzed for those comparisons. These registry entries describe the study question and some features of the analysis.

They do not establish what the primary outcome showed. The record does not give the observed means or changes, the group difference, a confidence interval, or a p-value for nerve conduction. Without those results, it is not possible to determine the direction or magnitude of any difference, or how precisely it was estimated. The endpoint description alone is not evidence that one treatment was better, worse, or equivalent to the other.

The study summary also discusses endothelial-dependent and heat-induced vasodilation, but the recorded primary outcome is nerve conduction. Those are distinct outcome descriptions, and the registry information does not provide numerical results for either in the material recorded for the primary endpoint. The primary timeframe is listed as one year, while treatment and assessment timing are described differently elsewhere in the record; that relationship is not clarified.

General statistical context: a non-significant result, if reported, would not by itself prove that two treatments have the same effect. Likewise, an apparent difference would need to be considered alongside its uncertainty, study design, outcome definition, and multiplicity. Here, even that assessment is not possible because the primary numerical findings are not reported in the registry record. The adverse-event counts offer limited descriptive safety information but do not fill the gap in efficacy results or establish causation.

The appropriate conclusion is therefore limited: the record documents the trial’s design and outcome description, but does not contain enough primary-result information to judge the observed treatment comparison. This is a limitation of the registry information, not a conclusion that the trial found no effect.

13. Why This Trial Matters Statistically

This trial illustrates why a registry entry should be read in two stages: first identify the question and design, then check whether the recorded results contain estimates that answer the question. The record describes randomization, triple masking, parallel groups, the active treatment and placebo, and a nerve conduction endpoint. It also gives an analyzed count for each arm. These details help define the comparison, but do not substitute for the outcome estimates.

The distinction is especially important for a continuous endpoint described through multiple nerve measures. A mean and its standard error can summarize a group, but the treatment comparison requires a defined contrast and information about uncertainty. The registry provides neither for the primary outcome. Thus, a reader cannot judge the size, direction, or precision of the difference from the record, even though the endpoint and analysis counts are described.

The record also demonstrates how endpoint multiplicity and timing affect interpretation. Several nerves and measurement types are named, nine outcome measures are listed, and the primary timeframe is one year, while the summary describes treatment and assessments over six months. Without the statistical plan and a clear mapping from measurements to the primary analysis, readers cannot determine how the outcome family was prioritized or how time points were incorporated.

Finally, safety counts need their own cautious reading. Serious and other adverse events are reported separately, but no comparative uncertainty analysis is given, and the death fields are null rather than explicit zero counts. These limitations do not negate the value of the trial design information. They show why transparent result estimates, analysis definitions, and missing-data procedures are essential for drawing statistical conclusions from a clinical trial record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation is that the registry describes the primary nerve conduction outcome without reporting its numerical results. Means, standard errors, treatment contrasts, confidence intervals, and p-values are not reported in the registry record. The primary outcome description names multiple nerves and includes both velocities and amplitudes, while its title emphasizes changes in amplitude; the record does not clarify which precise measure defines the primary comparison.

The timing is also unclear. The primary outcome timeframe is listed as one year, whereas the summary describes six months of treatment and assessments after three and six months. The record does not explain whether the one-year timeframe refers to follow-up, endpoint measurement, or another feature of data collection. The statistical plan and the handling of multiple outcomes and measurements are not reported.

The analysis count is described as 19 participants in each arm, but participant flow and analysis-population definitions are not reported. It is therefore not possible to determine from the record how this count relates to the randomized population, whether measurements were missing, or how missingness was handled. Baseline characteristics and the details of the randomization and masking procedures are also not reported in the registry record.

The adverse-event information is limited to counts and listed serious-event terms. Comparative uncertainty, attribution, and the meaning of null death entries are not clarified. These limitations constrain interpretation of both the primary outcome and safety information; they do not establish what the unreported analyses found.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Lovaza® and Microvascular Function in Type 2 Diabetes — NCT00931879.
• Registry record last updated 2017-05-09; status last verified 2017-03.
• Results first posted 2017-05-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a completed, randomized, triple-masked, parallel-group phase 4 trial sponsored by Eastern Virginia Medical School. It lists enrollment of 44 and compares omega-3-ethyl esters, identified as 4 g of Lovaza per day, with placebo. The study summary describes six months of treatment in people with type 2 diabetes, neuropathy, and elevated triglyceride levels.

The primary outcome is described as changes in nerve conduction amplitude, with a one-year timeframe. The record states that 19 participants in each arm were analyzed, but does not report numerical primary-outcome results or the statistical analysis plan. It lists nine outcome measures. Serious and other adverse-event counts are recorded for both arms; death counts are null. The registry therefore supplies design and descriptive information, but not enough primary-result detail to estimate or interpret the treatment-group difference.